References

1. FDA Guidance on Exposure-Response Relationships: Study Design, Data Analysis, and Regulatory Applications (May 2003), www.fda.gov/cder.

2. Huang, S.M.; Miller, M.; Toigo, T.; Chen, M.C; Sahajwalla, C.G.; Lesko, L.J.; Temple, R. Evaluation of Drugs in Women: Regulatory Perspective—in Section 11, Drug Metabolism/Clinical Pharmacology (section editor: Schwartz, J). In Principles of Gender-Specific Medicine, Legato, M., Ed.; Academic Press.

3. Beierle, I.; Meibohm, B.; Derendorf, H. Gender Differences in Pharmacokinetics and Pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 1999 Nov, 37 (11), 529547.

4. Frackiewicz, E.J.; Sramek, J.J.; Cutler, N.R. Gender Differences in Depression and Antidepressant Pharmacokinetics and Adverse Events. Ann. Phannacother. 2000, Jan, 34 (1), 80-88.

5. Vinge, E. Men and Women Respond Differently to Drugs. Hormonedependent Pharmacodynamic Differences are Rarely Studied. Lakartidningen 1998 Jul 8, 95 (2829), 3177-3182.

6. Clarke, S.; Jones, B. Human Cytochrome P450 and their Role in

Metabolismbased Drug-Drug Interactions. In Drug-Drug Interactions, David Rodrigues, A., Ed.; Marcel Dekker, Inc, 2001; 55-88.

7. Gleiter, C.H.; Gundert-Remy, U. Gender Differences in Pharmacokinetics. Eur. J. Drug. Metab. Pharmacokinet. 1996, Apr-Jun, 21 (2), 123-128.

8. Harris, R.Z.; Benet, L.Z.; Schwartz, J.B. Gender Effects in Pharmacoki-netics and Pharmacodynamics. Drugs, 1995 Aug, 50 (2), 222-239.

9. Schwartz, J.B. Gender and Dietary Influences on Drug Clearance. J. Gend. Specif. Med. 2000, 30-32.

10. Levy, G. Predicting Effective Drug Concentrations for Individual Patients. Determinants of Pharmacodynamic Variability. Clin. Pharmacokinet. 1998 Apr, 34 (4), 323-333.

11. Kashuba, A.D.; Nafziger, A.N. Physiological Changes During the Menstrual Cycle and Their Effects on the Pharmacokinetics and Pharmacodynamics of Drugs. Clin. Pharmacokinet. 1998 Mar, 34 (3), 203-218.

12. Lewis-Hall, F. Gender Differences in Psychotropic Medications. Mt Sinai J. Med. 1996 Oct-Nov, 63 (5-6), 326-329.

13. Fankhauser, M.P. Psychiatric Disorders in Women: Psychopharmacologic Treatments. J. Am. Pharni. Assoc. (Wash). 1997 Nov-Dec, NS37 (6), 667-678.

14. Fletcher, C.V.; Acosta, E.P.; Strykowski, J.M. Gender Differences in Human Pharmacokinetics and Pharmacodynamics. J. Adolesc. Health. 1994 Dec, 15 (8), 619-629.

15. Bonate, P, L. Gender-related Differences in Xenoblotic Metabolism. J. Clin. Pharmacol. 1991 Aug, 31 (8), 684-690.

16. Dawkins, K.; Potter, W.Z. Gender Differences in Pharmacokinetics and Pharmacodynamics of Psychotropics: Focus on Women. Psychopharmacol. Bull. 1991, 27 (4), 417-426.

17. Meibohm, B.; Beierle, L; Derendorf, H. How Important Are Gender Differences in Pharmacokinetics? Clin. Pharmacokin. 2002, 41 (5), 329-342.

18. Skett, P. Biochemical Basis of Sex Differences in Drug Metabolism. Pharmacol. Ther. 1988, 38 (3); 269-304.

19. Wilson, K. Sex-related Differences in Drug Disposition in Man.: Clin: Pharmacokinet. 1984 May-Jun, 9 (3); 189-202.

20. Schwartz, J.B. The Influence of Sex on Pharmacokinetics. Clin. Pharmaco-kinet. 2003, 42 (2); 107-121.

21. The study and evaluation of gender differences in the clinical evaluation of drugs; Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs: Federal Register, Notice. 58:39406-39416, 1993.

22. Greenblatt, D.J.; Divoll, M.K.; Abernethy, D.R.; Ochs, H.R.; Harmatz, J. S.; Shader, R.I. Age and Gender Effects on Chlordiazepoxide Kinetics: Relation to Antipyrine Disposition Pharmacology. 1989, 38 (5), 327-334.

23. Kando, J.C.; Yonkers, K.A.; Cole, J.O. Gender as a Risk Factor for Adverse Events to Medications, Drugs. 1995 Jul, 50 (1), 1-6.

24. Peck, R.W.; Wootton, R.; Wiggs, R.; Layton, G.; Posner, J. Effect of Food and Gender on the Pharmacokinetics of Tucaresol in Healthy Volunteers. Br. J. Clin. Pharmacol. 1998 Jul, 46 (1), 83-86.

25. Mesnil, F.; Mentre, F.; Dubruc, C.; Thenot, J.P.; Mallet, A. Population

Pharmacokinetic Analysis of Mizolastine and Validation from Sparse Data on Patients using the Nonparametric Maximum Likelihood Method.: J. Pharmacokinet. Biopharm. 1998 Apr, 26 (2), 133-161.

26. Greenblatt, D.J.; Abernethy, D.R.; Locniskar, A.; Harmatz, J.S.; Limjuco, R.A.; Shader, R.I. Effect of Age, Gender, and Obesity on Midazolam Kinetics. Anesthesiology. 1984 Jul, 61 (1), 27-35.

27. Notice, F.R. Guideline for the Format and Content of the Clinical and Statistical Sections of Application, <http://www.fda.gov/cder/guidance/index.htm>. 1988.

28. Institute of Medicine, Committee on Understanding the Biology of Sex and Gender Differences. Exploring the Biological Contributions to Human Health, Does Sex Matter?, Wizemann, T.M., Pardue, M.L., Eds.; National Academy Press: Washington DC, 2001.

29. Wood, A.J. Ethnic Differences in Drug Disposition and Response. Ther. Drug Monit. 1998 Oct, 20 (5), 525-526.

30. Johnson, J.A. Predictability of the Effects of Race or Ethnicity on Pharmacokinetics of Drugs. Int. J. Clin. Pharmacol. Ther. 2000 Feb, 38 (2), 53-60.

31. Johnson, J.A. Influence of Race or Ethnicity on Pharmacokinetics of Drugs. J. Pharm. Sci. 1997 Dec, 86 (12), 1328-1333.

32. Evans, W.E.; Johnson, J.A. Pharmacogenomics: the Inherited Basis for Interindividual Differences in Drug Response. Annu. Rev. Genomics Hum. Genet. 2001, 2, 9-39.

33. Wood, A.J.; Zhou, H.H. Ethnic Differences in Drug Disposition and Responsiveness. Clin. Pharmacokinet. 1991 May, 20 (5), 350-373.

34. Zhou, H.H.; Liu, Z.O.; Ethnic Differences in Drug Metabolism. Clin. Chem. Lab Med. 2000 Sep, 38 (9); 899-903.

35. Kalow, W. Interethnic Differences in Drug Response. In Pharmacogenomics, Kalow, W., Myer, U.A., Tyndale, R., Eds.; New York: Marcel Dekker, 2001; 109-134.

36. Kalow, W.; Bertilsson, L. Interethnic Factors Affecting Drug Response. Adv. Drug Res. 1994, 25, 1-59.

37. Levy, R.A. Ethnic and Racial Differences in Response to Medicines: Preserving Individualized Therapy in Managed Pharmaceutical Programmes. Pharm. Med. 1993, 7, 139-165.

38. Xie, H.-G.; Kim, R.B.; Wood, A.J.J.; Stein, C.M. Molecular Basis of Ethnic Differences in Drug Disposition and Response. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 815-850.

39. Bjornsson, T.D.; Wagner, J.A.; Donahue, S.R.; Harper, D.; Karim, A., et al. A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness. J. Clin. Pharmacol. 2003, 43, 943-967.

40. William, E.; Evans, * Mary, V. Relling: Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics; Science. 1999 Oct 15, 286 (5439), 487-491.

41. Grant, D.; Tang, B.; Kalow, W. Variability in Caffine Metabolism. Clin. Pharmacol. Ther. 1983, 33, 591-602.

42. Fleisher, D.; Li, C; Zhou, Y.; Pao, L.H.; Karim, A. Drug, Meal and Formulation

Interactions Influencing Drug Absorption After Oral Adminis-tration: Clinical Implications. Clin. Pharmacokinet. 1999, 36 (3), 233-254.

43. Tschanz, C.; Stargel, W.W.; Thomas, J.A. Interactions Between Drugs and Nutrients. Adv. Pharmacol. 1996, 35, 1-26.

44. Perel, J.M.; Yurasits, L.; Brown, C.; Schulberg, H.C. Implications of Pharmacologic Assessments of Nortriptyline Compliance. Clin. Pharmacol. Ther. 1998, 63, 238.

45. Brown, R.O.; Dickerson, R.N. Drug-Nutrient Interactions. Am. J. Manag. Care 1999, 5 (3), 345-352.

46. Jusko, W.J. Role of Tobacco Smoking in Pharmacokinetics. J. Pharmacokin. Biopharm. 1978, 6, 7-39.

47. Lacombe, P.S.; Vincent, J.A.G.; Pages, J.C.; Morselli, P.I. Causes and Problems of Nonresponse or Poor Response to Drugs. Drugs 1996, 57, 552-570.

48. Thomas, J.A. Drug-Nutrient Interactions. Nutr. Rev.1995, 53 (10), 271-282.

49. Harris, R.Z.; Jang, G.R. Tsvuoda: Effects S: Dietary Effects on Drug Metabolism and Transport—Clin. Pharmacokinetic. 2003, 42 (13), 1071-1088.

50. Kinirons, M.T.; Crome, P. Clinical Pharmacokinetic Considerations in Elderly. Clin. Pharmacokinet. 1977, 33 (4), 302-312.

51. Crome, P. What's Different About Older People. Toxicology 2003 Oct 1, 192 (1), 49-54.

52. Vuyk, J. Pharmacodynamics in the Elderly. Best Pract. Res. Clin. Anaesthesiol. 2003 Jun, 17 (2), 207-218.

53. Sadean, M.R.; Glass, P.S. Pharmacokinetics in the Elderly. Best Pract. Res. Clin. Anaesthesiol. 2003 Jun, 17 (2), 191-205.

54. Jansen, P.A.; Clinically Relevant Drug Interactions in the Elderly. Ned Tijdschr Geneeskd. 2003 Mar 29, 147 (13), 595-599.

55. Skirvin, J.A.; Lichtman, S.M. Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer. Drugs Aging 2002, 19 (1), 25-42.

56. Benedetti, S.M.; Baltes, E.L. Drug Metabolism and Disposition in Children. Fundam. Clin. Pharmacol. 2003 Jun, 17 (3), 281-299.

57. ICH harmonized tripartite guideline. Clinical investigation of medicinal products in the pediatric population. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 20 July, 2000.

58. Oilman, J.T. Therapeutic Drug Monitoring in the Pediatric and Neonate Age Group-Problems and Clinical Pharmacokinetic Implications. Clin. Phamacokin. 1990, 19, 1-10.

59. Grand, R.J.; Watkins, J.B.; Torti, F.M. Development of the Human Gastrointestinal Tract: A Review. Gastroenterology 1976, 70, 790-810.

60. Kerlin, P.; Zinsmeister, A.; Phillips, S. Relationship of Motility to Flow of Contents in the Human Small Intestine. Gastroenterology 1982, 82, 701-706.

61. Pedersen, S.; Steffensen, G. Absorption Characteristics of Once-a-Day Slow-Release Theophylline Preparation in Children with Asthma. J. Pediatr. 1987, 110, 953-959.

62. Rane, A.; Wilson, J.T. Clinical Pharmacokinetics in Infants and Children. Clin. Pharmacokin. 1976, 2, 2-24.

63. Routledge, P.A. Pharmacokinetics in Children. J. Antimicrob. Chemother. 1994, 34, 19-24.

64. Buchanan, N. Pediatric Clinical Pharmacology and Therapeutics. In Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd Ed.; Speight, T.M. Ed.; ADIS Press: Aukland, 1987, 118-159.

65. Oloive, G. Pharmacocine' tique et biotransformation des me' dicaments chez I'enfant. Louvain Med. 1991, 110, 565-569.

66. Pariente-Khayat, A.; Treluyer, J.M.; Rey, E. Paramacokinetics and Tolerance of Flunitrazepam in Neonates and Infants. Clin. Pharmacol. and Ther. 1999, 6, 136-139.

67. Jeruss, J.; Braun, S.V.; Reese, J.C.; Guillot, A. Cyclosporine-induced White and Grey Matter Central Nervous System Lesions in Pediatric Renal Transplant Patient. Pediatr. Transplantation 1988, 2, 45-50.

68. Martin, L.D.; Bratton, S.L.; O'Rourke, P.P. Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children. Crit. Care Med. 1999 Jul, 27 (7), 1358-1368.

69. Vitiello, B. Current Research Highlights in Child and Adolescent Psychopharmacology. Cur. Psychiatry Rep. 2000 Apr, 2 (2), 110-116.

70. Cheymol, G. Effects of Obesity on Pharmacokinetics Implications for Drug Therapy. Clin. Pharmacokinet. 2000, 39 (3), 215-231.

71. Pietrobelli, A.; Faith, M.S.; Allison, D.B.; Gallagher, D.; Chiumello, G.; Heymsfield, S.B. Body Mass Index as a Measure of Adiposity Among Children and Adolescents: A Valiadation Study. J. Pedaitr. 1998, 132, 204-210.

72. Policy Statement (Committee on Nutrition); Prevention of Pediatric Overweight and Obesity, Pediatrics August 2003, 112 (2), 424-430.

73. Blouin, R.A.; Warren, G.W. Pharmacokinetic Considerations in Obesity. J. Pharm. Sci. 1999, 88 (1), 1-7.

74. Jung, D.; Mayersohn, M.; Perrier, D.; Calkins, J.; Saunders, R. Thiopental Disposition in Lean and Obese Patients Undergoing Surgery. Anesthesiology 1982, 56, 269-274.

75. Benedek, I.H.; Fiske, W.D.; Griffen, W.O.; Bell, R.M.; Blouin, R.A.; McNamara, P.J. Serum Alpha 1-Acid-Glycoprotein and the Binding of Drugs in Obesity. Br. J. Clin Pharmacol. 1983, 16, 751-754.

76. Abernethy, D.R.; Greenblatt, D.J. Phenytoin Disposition in Obesity. Arch. Neurol. 1985, 42, 468-471.

77. Benedek, I.H.; Blouin, R.A.; McNamara, P.J. Serum Protein Binding and the Role of Increased Alpha 1-acid-Glycoprotein in Moderately Obese Male Subjects. Br. J. Clin Pharmacol. 1984, 18, 941-946.

78. Kotlyar, M.; Carson, S.W. Effects of Obesity on the Cytochrome P450 Enzyme System. Int. J. Clin. Pharmacol. Ther. 1999, 37 (1), 8-19.

79. Greenblatt, D.J.; Abernethy, D.R.; Boxenbaum, H.G.; Matlis, R.O.; Ochs, H.R.; Harmatz, J.S.; Shader, R.J. Influence of Age Gender and Obesity on Salicylate Kinetics Following Dose of Asprin. Arthritis Rheum. 1986, 29, 971-980.

80. Christoff, P.B.; Conti, D.R.; Nayor, C; Jusko, W.J. Procainimide Disposition in Obesity. Drug Intell. Clin. Pharm. 1983, 23, 369-376.

81. Davis, R.L.; Quenzer, R.W.; Bozigian, H.P.; Warner, C.W.; Pharmacokinetics of

Ranitidinein Morbidly Obese Women, DICP. Ann. Pharmacother. 1990, 24, 1040-1043.

82. Stokholm, K.H.; Brochner-Mortenson, J.; Hoilund-Carlsen, P.F. Glomerular Filtration Rate and Adrenocortical Function in Obese Women. Int. J. Obes. 1980, 4, 57-63.

83. Dionne, R.E.; Bauer, L.A.; Gibson, G.A.; Griffen, W.O.; Blouin, R.A. Estimating Creatinine Clearance in Morbidly Obese Patients. Am. J. Hosp. Pharm. 1981, 38, 841-844.

84. Reiss, R.A.; Hass, C.E.; Karki, S.D.; Gumbiner, B.; Welle, S.L.; Carson, S. W.; Lithium Pharmacokinetics in Obese. Clin. Pharmacol. Ther. 1994, 55, 392-398.

85. DePaulo, J.R.; Correa, E.J.; Sapir, D.G. Renal Toxicity of Lithium and its Implications. Johns hopkins Med. J. 1981, 149, 15-21.

86. Georgiadis, M.S.; Steinberg, S.M.; Hankins, D.C.; Johnson, B.E. Obesity and Therapy Related Toxicity in Patients Treated for Small-cell Lung Cancer. J. Nat. Cancer Inst. 1995, 87, 361-366.

87. Varin, F.; Ducharme, J.; Theoret, Y.B.; Bevan, D.R.; Donati, F.; Influence of Exterme Obesity on the Body Disposition and Neuromuscular Blocking Effect of Atracurium. Clin. Pharmacol. Ther. 1990, 48, 18-25.

88. Waud, B.E.; Waud, D.R. Turboaurarine Sensetivity of the Diaphragm after Limb Immobilization. Anesth. Analg. 1986, 65, 493-495.

89. FDA Gender guideline, Section on "Women of childbearing potential" General consideration for the clinical evaluation of drugs (HEW publication No. FDA 77-3040), 1997.

90. FR notice: Guidance on the Agency's use of the refusal-to-file (RTF) option per Code of Federal Register (CFR) 314.101(d)(3), February 11,1998, 63 (28), 1993, 6854-6862.

91. FR notice. "Final Rule on Investigational New Drug Applications and New Drug Applications", 1998.

92. ICH E3 (1996) Structure and Content of Clinical Study Reports, http:// www.fda.gov/cder/guidance/index.htm.

93. Sahajwalla, C.; Mehta, M.; Chow, W. OWH report on gender differences in PK and PD of drugs in NDAs submitted to CDER between 1994 and 2000, 2001.

94. Toigo, T.; Struble, K.; Behrman, R.; Birnkrant, D.; Gitterman, S.; Robins, B. Eligibility of Women to Participate in Clinical Trials: CDER, FDA, June 1999.

95. NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical research-amended October 2001. http://grantsl.nih.gov/grants/ funding/women_min/guidelines_amended_l0_2001.htm

96. Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials Jan 2003. http://www.fda.gov/cder/guidance/index.htm

97. Guidance for Industry: Population Pharmacokinetics. Center for Drug Evaluation and Research, United States Food and Drug Administration, 1999. http://www.fda.gov/cder/guidance/index.htm

98. FDA Guidance "Content and Format of the Adverse Reactions Section of Labeling" May 2000.

99. FR notice (2000): Labeling guideline (Federal Register 65:247; 81082-81131; December 22, 2000).

100. Evelyn, B.; Toigo, T.; Banks, D.; Pohl, D.; Gray, K.; Robins, B.; Ernat, J. Participation of Racial/Ethnic Groups in Clinical Trials and Race-Related Labeling: A Review of New Molecular Entities Approved 1995-1999. Journal of the National Medicine Association, Supplement. 2001 Dec, 93 (12).

101. FDA Guidance for Industry "Content and Format for Geriatric Labeling" October 2001. http://www.fda.gov/cder/guidance/index.htm

102. December 13, 1994, FDA final rule in the Federal Register (59 FR 64240); On August 15, 1997, FDA published proposed regulations in the Federal Register (62 FR 43899).

103. FDA Guidance for Industry "The Content and Format for Pediatric Use Supplements" May 1996. http://www.fda.gov/cder/guidance/index.htm

Was this article helpful?

0 0

Post a comment